Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6496)
All Articles published online
|
Publishing Process of This Article
|
Aug 28, 2014 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Xie Y, Zhu Y, Zhou H, Lu ZF, Yang Z, Shu X, Guo XB, Fan HZ, Tang JH, Zeng XP, Wen JB, Li XQ, He XX, Ma JH, Liu DS, Huang CB, Xu NJ, Wang NR, Lu NH. Furazolidone-based triple and quadruple eradication therapy for |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i32/11415.htm |
| Number | Citing Articles |
| 1 |
Youn I Choi, Sang-Ho Jeong, Jun-Won Chung, Dong Kyun Park, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim, Seol So, Jeong Hoon Lee, Jin-Young Jeong, Sun-Mi Lee. Rifabutin and Furazolidone Could Be the Candidates of the Rescue Regimen for Antibiotic-Resistant H. pylori in Korea. Canadian Journal of Infectious Diseases and Medical Microbiology 2019; 2019: 1 doi: 10.1155/2019/9351801
|
| 2 |
Yi Hu, Yin Zhu, Nong-Hua Lu. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Frontiers in Cellular and Infection Microbiology 2017; 7 doi: 10.3389/fcimb.2017.00168
|
| 3 |
Yi Hu, Yin Zhu, Nong-hua Lu. Primary Antibiotic Resistance of Helicobacter pylori in China. Digestive Diseases and Sciences 2017; 62(5): 1146 doi: 10.1007/s10620-017-4536-8
|
| 4 |
Chao-ran Ji, Jing Liu, Yue-yue Li, Chuan-guo Guo, Jun-yan Qu, Yan Zhang, Xiuli Zuo. Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis. BMJ Open 2020; 10(10): e037375 doi: 10.1136/bmjopen-2020-037375
|
| 5 |
You‐hua Wang, Zhi‐fa Lv, Yao Zhong, Dong‐sheng Liu, Shu‐ping Chen, Yong Xie. The internalization of Helicobacter pylori plays a role in the failure of H. pylori eradication. Helicobacter 2017; 22(1) doi: 10.1111/hel.12324
|
| 6 |
Muhammad Miftahussurur, Hafeza Aftab, Pradeep Krishna Shrestha, Rabi Prakash Sharma, Phawinee Subsomwong, Langgeng Agung Waskito, Dalla Doohan, Kartika Afrida Fauzia, Yoshio Yamaoka. Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. Antimicrobial Resistance & Infection Control 2019; 8(1) doi: 10.1186/s13756-019-0482-x
|
| 7 |
Yi Hu, Yin Zhu, Nong-Hua Lu. The management of Helicobacter pylori infection and prevention and control of gastric cancer in China. Frontiers in Cellular and Infection Microbiology 2022; 12 doi: 10.3389/fcimb.2022.1049279
|
| 8 |
Jie Pan, Zhengchao Shi, Dingsai Lin, Ningmin Yang, Fei Meng, Lang Lin, Zhencheng Jin, Qingjie Zhou, Jiansheng Wu, Jianzhong Zhang, Youming Li. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial. Frontiers of Medicine 2020; 14(1): 43 doi: 10.1007/s11684-019-0706-8
|
| 9 |
Yan Zhou, Zishao Zhong, Shengjuan Hu, Jing Wang, Yanhong Deng, Ximei Li, Xianmei Chen, Xue Li, Yuanyuan Tang, Xiaofei Li, Qian Hao, Jun Liu, Tian Sang, Yang Bo, Feihu Bai.
A Survey of
Helicobacter pylori
Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China
. Antimicrobial Agents and Chemotherapy 2022; 66(6) doi: 10.1128/aac.02188-21
|
| 10 |
Chongshan Dai, Lei Lei, Bin Li, Yang Lin, Xilong Xiao, Shusheng Tang. Involvement of the activation of Nrf2/HO-1, p38 MAPK signaling pathways and endoplasmic reticulum stress in furazolidone induced cytotoxicity and S phase arrest in human hepatocyte L02 cells: modulation of curcumin. Toxicology Mechanisms and Methods 2017; 27(3): 165 doi: 10.1080/15376516.2016.1273424
|
| 11 |
Yong Xie, Zhenyu Zhang, Junbo Hong, Wenzhong Liu, Hong Lu, Yiqi Du, Weihong Wang, Jianming Xu, Xuehong Wang, Lijuan Huo, Guiying Zhang, Chunhui Lan, Xiaoyan Li, Yanqing Li, Hong Wang, Guoxin Zhang, Yin Zhu, Xu Shu, Ye Chen, Jiangbin Wang, Nonghua Lu. Furazolidone‐containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China. Helicobacter 2018; 23(5) doi: 10.1111/hel.12496
|
| 12 |
Liya Zhuge, Youhua Wang, Shuang Wu, Ru‐Lin Zhao, Zhen Li, Yong Xie. Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta‐analysis. Helicobacter 2018; 23(2) doi: 10.1111/hel.12468
|
| 13 |
Chen Qiao, Yueyue Li, Jing Liu, Chaoran Ji, Junyan Qu, Junnan Hu, Rui Ji, Meng Wan, Boshen Lin, Minjuan Lin, Qingqing Qi, Xiuli Zuo, Yanqing Li. Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area. Journal of Gastroenterology and Hepatology 2021; 36(9): 2383 doi: 10.1111/jgh.15468
|
| 14 |
Luyi Chen, Jiamin He, Lan Wang, Qiwei Ge, Hua Chu, Yujia Chen, Xiaoli Chen, Yanqin Long, Yanyong Deng, Huiqin He, Aiqing Li, Shujie Chen. Efficacies of different proton pump inhibitor-based 14-day bismuth–furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial. Clinical and Experimental Medicine 2018; 18(4): 569 doi: 10.1007/s10238-018-0510-9
|
| 15 |
Ya-Wen Zhang, Wei-Ling Hu, Yuan Cai, Wen-Fang Zheng, Qin Du, John J Kim, John Y Kao, Ning Dai, Jian-Min Si. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for <i>Helicobacter pylori</i> infection and predictors of failed eradication. World Journal of Gastroenterology 2018; 24(40): 4596-4605 doi: 10.3748/wjg.v24.i40.4596
|
| 16 |
Chongshan Dai, Daowen Li, Lijing Gong, Xilong Xiao, Shusheng Tang. Curcumin Ameliorates Furazolidone-Induced DNA Damage and Apoptosis in Human Hepatocyte L02 Cells by Inhibiting ROS Production and Mitochondrial Pathway. Molecules 2016; 21(8): 1061 doi: 10.3390/molecules21081061
|
| 17 |
Conghua Song, Xing Qian, Yin Zhu, Xu Shu, Yanping Song, Zhijuan Xiong, Jianfang Ye, Tao Yu, Ling Ding, Hui Wang, Nonghua Lu, Yong Xie. Effectiveness and safety of furazolidone‐containing quadruple regimens in patients with Helicobacter pylori infection in real‐world practice. Helicobacter 2019; 24(4) doi: 10.1111/hel.12591
|
| 18 |
Tian Geng, Zhong-Su Yu, Xi-Xi Zhou, Bo Liu, Hui-Hua Zhang, Zhong-Yue Li. Antibiotic resistance of Helicobacter pylori isolated from children in Chongqing, China. European Journal of Pediatrics 2022; 181(7): 2715 doi: 10.1007/s00431-022-04456-1
|
| 19 |
Syed Fahim Shah, Sohail Aziz Paracha, Waheed Ullah, Iqbal Muhammad, Somaid Iqbal, Aisha Gul, Mudassir Hussain, Hafiz Ullah, Sadir Zaman. Success of 14-day triple and quadruple therapy for the control of Helicobacter pylori infections in Kohat district. Drug Target Insights 2022; 16(1): 49 doi: 10.33393/dti.2022.2481
|
| 20 |
Yong Xie, Zhenhua Zhu, Jiangbin Wang, Lingxia Zhang, Zhenyu Zhang, Hong Lu, Zhirong Zeng, Shiyao Chen, Dongsheng Liu, Nonghua Lv. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China. Antimicrobial Agents and Chemotherapy 2018; 62(9) doi: 10.1128/AAC.00432-18
|
| 21 |
Wen Zhong Liu, Yong Xie, Hong Lu, Hong Cheng, Zhi Rong Zeng, Li Ya Zhou, Ye Chen, Jiang Bin Wang, Yi Qi Du, Nong Hua Lu. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter 2018; 23(2) doi: 10.1111/hel.12475
|
| 22 |
Jie Hu, Hao Mei, Na‐yun Su, Wen‐jing Sun, De‐kui Zhang, Li‐lin Fan, Ping He, Jie Pan, Xing‐wei Wang, Pei‐ying Zou, Yu‐xiang Liu, Yan Guo, Chun‐Hui Lan. Eradication rates of Helicobacter pylori in treatment‐naive patients following 14‐day vonoprazan‐amoxicillin dual therapy: A multicenter randomized controlled trial in China. Helicobacter 2023; 28(4) doi: 10.1111/hel.12970
|
| 23 |
Jing Li, Huiying Shi, Fang Zhou, Li Xie, Rong Lin. The Efficacy and Safety of Regimens for Helicobacter pylori Eradication Treatment in China. Journal of Clinical Gastroenterology 2024; 58(1): 12 doi: 10.1097/MCG.0000000000001902
|
| 24 |
Dong-Min Yi, Tao-Tao Yang, Shuai-Heng Chao, Ya-Xin Li, Ying-Lei Zhou, Hai-Hui Zhang, Ling Lan, Yu-Wei Zhang, Xue-Mei Wang, Yan-Rui Zhang, Jian Li, Song-Ze Ding. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study. Medicine 2019; 98(6): e14408 doi: 10.1097/MD.0000000000014408
|
| 25 |
Jingshu Chi, Canxia Xu, Xiaoming Liu, Hao Wu, Xiaoran Xie, Peng Liu, Huan Li, Guiying Zhang, Meihua Xu, Chaomin Li, Chunlian Wang, Fengqian Song, Ming Yang, Jie Wu. A Comparison of Doxycycline and Amoxicillin Containing Quadruple Eradication Therapy for Treating Helicobacter pylori-Infected Duodenal Ulcers: A Multicenter, Opened, Randomized Controlled Trial in China. Pathogens 2022; 11(12): 1549 doi: 10.3390/pathogens11121549
|
| 26 |
Shumei Ma, Zhao Jin, Yi Liu, Lin Liu, Hao Feng, Ping Li, Zhujun Tian, Minghua Ren, Xiaodong Liu, Ana Lloret. Furazolidone Increases Survival of Mice Exposed to Lethal Total Body Irradiation through the Antiapoptosis and Antiautophagy Mechanism. Oxidative Medicine and Cellular Longevity 2021; 2021: 1 doi: 10.1155/2021/6610726
|
| 27 |
Anthony O'Connor, Javier P. Gisbert, Colm O'Morain, Spiros Ladas. Treatment of Helicobacter pylori Infection 2015. Helicobacter 2015; 20(S1): 54 doi: 10.1111/hel.12258
|
| 28 |
Huan Li, Xiu-Juan Xia, Lin-Fang Zhang, Jing-Shu Chi, Peng Liu, Hao Wu, Xiao-Ran Xie, De-Lin Tian, Kai-Xiao Kun, Ren-jie Gong, Xiao-Ming Liu, Can-Xia Xu. Comparative study of allicin-containing quadruple therapy vs. bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a prospective randomized study. European Journal of Gastroenterology & Hepatology 2021; 32(2): 194 doi: 10.1097/MEG.0000000000001896
|
| 29 |
Jian Fang Ye, Jun Bo Hong, Yin Zhu, Yong Xie, Xu Shu, Ling Yu Luo, Chuan Xie, Zhen Hua Zhu, Nong Hua Lu. Evaluation of first‐line bismuth‐containing 7‐day concomitant quintuple therapy for Helicobacter pylori eradication. Journal of Digestive Diseases 2017; 18(12): 704 doi: 10.1111/1751-2980.12559
|
| 30 |
Dmitry S. Bordin, Irina N. Voynovan, Aiman S. Sarsenbaeva, Oleg V. Zaytsev, Rustam A. Abdulkhakov, Natalia V. Bakulina, Igor G. Bakulin, Marina F. Osipenko, Maria A. Livzan, Sergei A. Alekseenko. Effectiveness of empirical <i>Helicobacter pylori</i> eradication therapy with furazolidone in Russia: results from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg). Terapevticheskii arkhiv 2023; 95(2): 120 doi: 10.26442/00403660.2023.02.202107
|
| 31 |
Sandra Martínez‐Puchol, Cláudia Gomes, Maria J. Pons, Lidia Ruiz‐Roldán, Alba Torrents de la Peña, Theresa J. Ochoa, Joaquim Ruiz. Development and analysis of furazolidone‐resistant Escherichia coli mutants. APMIS 2015; 123(8): 676 doi: 10.1111/apm.12401
|
| 32 |
Junxian Wang, Yuping Cao, Wei He, Xiaoping Li. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. Medicine 2021; 100(51): e28323 doi: 10.1097/MD.0000000000028323
|